Tablet containing composite with cyclodextrin
Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin in a ratio ranging from 1:8 to 1:20.
1. A tablet comprising, as an active ingredient, N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, wherein N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof forms a composite with hydroxypropyl-β-cyclodextrin in a ratio ranging from 1:8 to 1:20 by weight, wherein the tablet comprises (1) the composite in an amount of about 85% by weight or more of the total weight of the tablet, (2) a lubricant selected from the group consisting of calcium stearate and magnesium stearate in an amount of about 0.5 to 1.5% by weight of the total weight of the tablet, or a lubricant selected from the group consisting of talc and sodium stearyl fumarate in an amount of about 0.5 to 2.5% by weight of the total weight of the tablet, (3) a diluent selected from the group consisting of microcrystalline cellulose and D-mannitol in an amount of about 3 to 10% by weight of the total weight of the tablet, and (4) hydroxypropyl cellulose in an amount of about 0 to 4% by weight of the total weight of the tablet.
2. The tablet of claim 1 , wherein (2) magnesium stearate is in an amount of about 1% by weight of the total weight of the tablet, (3) a diluent is selected from the group consisting of microcrystalline cellulose and D-mannitol in an amount of about 4 to 7.5% by weight of the total weight of the tablet, and (4) hydroxypropyl cellulose is in an amount of about 0 to 4% by weight of the total weight of the tablet.
3. The tablet of claim 1 , which is a tablet obtainable by forming a composition comprising the composite into a tablet.
4. The tablet of any one of claim 1 , wherein the tablet is a coated tablet.
5. The tablet of claim 4 , wherein the coated tablet is a film coated tablet.
6. The tablet of claim 1 , wherein the composite is a composite of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin in a ratio of 1:10 by weight.
7. The tablet of claim 1 , wherein the composite is spray-dried powder.
8. The tablet of claim 1 , wherein the composite is lyophilized powder.
9. The tablet of claim 1 , wherein N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof is N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride.